{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:04:45Z","timestamp":1751515485851,"version":"3.41.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum. Genet."],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00439-025-02757-7","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T17:58:15Z","timestamp":1750269495000},"page":"695-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current perspectives on gene therapy and its involvement in curing genetic disorders"],"prefix":"10.1007","volume":"144","author":[{"given":"Shireen","family":"Nishad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipali","family":"Dongare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayani","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raskar Dhanashri","family":"Anil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"4","key":"2757_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ppul.25055","volume":"56","author":"NJ Abreu","year":"2021","unstructured":"Abreu NJ, Waldrop MA (2021) Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol 56(4):710\u2013720","journal-title":"Pediatr Pulmonol"},{"key":"2757_CR2","unstructured":"Ahmed N (2022) A systematic review of the efficacy of gene therapy for diabetes and diabetes-related complications"},{"key":"2757_CR3","doi-asserted-by":"crossref","unstructured":"Ahmed R et al. (2025) CRISPR\/Cas9 system as a promising therapy in Thalassemia and Sickle Cell Disease: a systematic review of clinical trials. Mol Biotechnol 1\u201310","DOI":"10.1007\/s12033-025-01368-x"},{"issue":"6","key":"2757_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/dmd.121.000418","volume":"50","author":"F Alhamadani","year":"2022","unstructured":"Alhamadani F et al (2022) Adverse drug reactions and toxicity of the food and drug administration\u2013approved antisense oligonucleotide drugs. Drug Metab Dispos 50(6):879\u2013887","journal-title":"Drug Metab Dispos"},{"key":"2757_CR5","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.2147\/IJN.S455574","volume":"19","author":"KS Allemailem","year":"2024","unstructured":"Allemailem KS et al (2024) Recent updates of the CRISPR\/Cas9 genome editing system: novel approaches to regulate its spatiotemporal control by genetic and physicochemical strategies. Int J Nanomed 19:5335\u20135363","journal-title":"Int J Nanomed"},{"issue":"5","key":"2757_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2174\/1570162X17666191025112918","volume":"17","author":"MJ Almeida","year":"2019","unstructured":"Almeida MJ, Matos A (2019) Designer nucleases: gene-editing therapies using CCR5 as an emerging target in HIV. Curr HIV Res 17(5):306\u2013323","journal-title":"Curr HIV Res"},{"key":"2757_CR7","unstructured":"Alyousfi DM (2022) Development and application of methods for resolving molecular diagnoses from patient sequence data for monogenic diseases. University of Southampton"},{"issue":"2","key":"2757_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/pro.3801","volume":"29","author":"JT Anderson","year":"2020","unstructured":"Anderson JT et al (2020) Context and number of noncanonical repeat variable diresidues impede the design of TALE proteins with improved DNA targeting. Protein Sci 29(2):606\u2013616","journal-title":"Protein Sci"},{"issue":"7785","key":"2757_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV et al (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576(7785):149\u2013157","journal-title":"Nature"},{"key":"2757_CR10","first-page":"33","volume":"8","author":"B Arjmand","year":"2020","unstructured":"Arjmand B et al (2020) The horizon of gene therapy in modern medicine: advances and challenges. Cell Biol Trans Med Stem Cells Regener Med 8:33\u201364","journal-title":"Cell Biol Trans Med Stem Cells Regener Med"},{"issue":"1","key":"2757_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s12038-020-00098-3","volume":"45","author":"MA Ashfaq","year":"2020","unstructured":"Ashfaq MA et al (2020) Post-transcriptional gene silencing: Basic concepts and applications. J Biosci 45(1):128","journal-title":"J Biosci"},{"issue":"3","key":"2757_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/cells11030417","volume":"11","author":"T Aslesh","year":"2022","unstructured":"Aslesh T, Yokota T (2022) Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells 11(3):417","journal-title":"Cells"},{"issue":"1","key":"2757_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines6010001","volume":"6","author":"T Aslesh","year":"2018","unstructured":"Aslesh T, Maruyama R, Yokota T (2018) Skipping multiple exons to treat DMD\u2014promises and challenges. Biomedicines 6(1):1","journal-title":"Biomedicines"},{"key":"2757_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gm2","volume":"1","author":"C Auffray","year":"2009","unstructured":"Auffray C, Chen Z, Hood L (2009) Systems medicine: the future of medical genomics and healthcare. Genome Med 1:1\u201311","journal-title":"Genome Med"},{"key":"2757_CR15","doi-asserted-by":"crossref","unstructured":"Badwal AK, Singh S (2024) A comprehensive review on the current status of CRISPR based clinical trials for rare diseases. Int J Biol Macromol 134097","DOI":"10.1016\/j.ijbiomac.2024.134097"},{"issue":"3","key":"2757_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrg2520","volume":"10","author":"JF Bateman","year":"2009","unstructured":"Bateman JF, Boot-Handford RP, Lamand\u00e9 SR (2009) Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. Nat Rev Genet 10(3):173\u2013183","journal-title":"Nat Rev Genet"},{"key":"2757_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","volume":"33","author":"DE Bauer","year":"2015","unstructured":"Bauer DE, Orkin SH (2015) Hemoglobin switching\u2019s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev 33:62\u201370","journal-title":"Curr Opin Genet Dev"},{"key":"2757_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcdb.2022.03.012","volume":"131","author":"B Bekaert","year":"2022","unstructured":"Bekaert B et al (2022) CRISPR\/Cas gene editing in the human germline. Semin Cell Dev Biol 131:93\u2013107","journal-title":"Semin Cell Dev Biol"},{"key":"2757_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","volume":"343","author":"G Bhattacharjee","year":"2022","unstructured":"Bhattacharjee G et al (2022) Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. J Control Release 343:703\u2013723","journal-title":"J Control Release"},{"key":"2757_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-018-4963-8","volume":"19","author":"K Blighe","year":"2018","unstructured":"Blighe K et al (2018) Gene editing in the context of an increasingly complex genome. BMC Genom 19:1\u201320","journal-title":"BMC Genom"},{"key":"2757_CR21","volume-title":"Inactivation of Hepatitis B Virus CCCDNA Using Engineered Transcription Activator-Like Effector Nucleases","author":"KM Bloom","year":"2013","unstructured":"Bloom KM (2013) Inactivation of Hepatitis B Virus CCCDNA Using Engineered Transcription Activator-Like Effector Nucleases. University of the Witwatersrand, Johannesburg (South Africa)"},{"key":"2757_CR22","doi-asserted-by":"crossref","unstructured":"Burgess SM (2020) Genome editing by targeted nucleases and the CRISPR\/Cas revolution. Liver Biol Pathobiol 953\u2013964","DOI":"10.1002\/9781119436812.ch71"},{"issue":"3","key":"2757_CR23","first-page":"245","volume":"33","author":"C Cakmak","year":"2021","unstructured":"Cakmak C, Zempel H (2021) A perspective on human cell models for POLG-spectrum disorders: advantages and disadvantages of CRISPR-Cas-based vs. patient-derived iPSC models. Med Gen 33(3):245\u2013249","journal-title":"Med Gen"},{"key":"2757_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev-biochem-060713-035418","volume":"83","author":"D Carroll","year":"2014","unstructured":"Carroll D (2014) Genome engineering with targetable nucleases. Annu Rev Biochem 83:409\u2013439","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"2757_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ymthe.2004.09.011","volume":"10","author":"BJ Carter","year":"2004","unstructured":"Carter BJ (2004) Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol Ther 10(6):981\u2013989","journal-title":"Mol Ther"},{"key":"2757_CR26","doi-asserted-by":"crossref","unstructured":"Cavazzana M et al (2024) Treating sickle cell disease: gene therapy approaches. Annual Rev Pharmacol Toxicol 65","DOI":"10.1146\/annurev-pharmtox-022124-022000"},{"issue":"5","key":"2757_CR27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jmb.2015.10.014","volume":"428","author":"S Chandrasegaran","year":"2016","unstructured":"Chandrasegaran S, Carroll D (2016) Origins of programmable nucleases for genome engineering. J Mol Biol 428(5):963\u2013989","journal-title":"J Mol Biol"},{"issue":"2","key":"2757_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","volume":"38","author":"S Chen","year":"2024","unstructured":"Chen S et al (2024) Splice-modulating antisense oligonucleotides as therapeutics for inherited metabolic diseases. BioDrugs 38(2):177\u2013203","journal-title":"BioDrugs"},{"issue":"8","key":"2757_CR29","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s12276-023-01057-2","volume":"55","author":"EH Choi","year":"2023","unstructured":"Choi EH et al (2023) Genome editing in the treatment of ocular diseases. Exp Mol Med 55(8):1678\u20131690","journal-title":"Exp Mol Med"},{"issue":"13","key":"2757_CR30","doi-asserted-by":"publisher","first-page":"10809","DOI":"10.3390\/ijms241310809","volume":"24","author":"AV Ciurea","year":"2023","unstructured":"Ciurea AV et al (2023) Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases and amyotrophic lateral sclerosis. Int J Mol Sci 24(13):10809","journal-title":"Int J Mol Sci"},{"issue":"282","key":"2757_CR31","first-page":"20143003","volume":"2015","author":"M Collins","year":"1821","unstructured":"Collins M, Thrasher A (1821) Gene therapy: progress and predictions. Proc Royal Soc B Biol Sci 2015(282):20143003","journal-title":"Proc Royal Soc B Biol Sci"},{"key":"2757_CR32","unstructured":"Conti RM et al (2021) Estimating the financial impact of gene therapy in the US"},{"key":"2757_CR33","unstructured":"Council NR et al. (2011) Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease"},{"issue":"2","key":"2757_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DBT Cox","year":"2015","unstructured":"Cox DBT, Platt RJ, Zhang F (2015) Therapeutic genome editing: prospects and challenges. Nat Med 21(2):121\u2013131","journal-title":"Nat Med"},{"issue":"1","key":"2757_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1006\/mthe.1999.0007","volume":"1","author":"MA Curran","year":"2000","unstructured":"Curran MA et al (2000) Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 1(1):31\u201338","journal-title":"Mol Ther"},{"issue":"5560","key":"2757_CR36","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1126\/science.1069883","volume":"295","author":"EH Davidson","year":"2002","unstructured":"Davidson EH et al (2002) A genomic regulatory network for development. Science 295(5560):1669\u20131678","journal-title":"Science"},{"issue":"2","key":"2757_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s40778-017-0077-5","volume":"3","author":"J Delhove","year":"2017","unstructured":"Delhove J, Qasim W (2017) Genome-edited T cell therapies. Curr Stem Cell Rep 3(2):124\u2013136","journal-title":"Curr Stem Cell Rep"},{"issue":"1","key":"2757_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10142-025-01529-w","volume":"25","author":"DB Dongare","year":"2025","unstructured":"Dongare DB, Nishad SS, Mastoli SY, Saraf SA, Srivastava N, Dey A (2025) High-throughput sequencing: a breakthrough in molecular diagnosis for precision medicine. Funct Integ Genom 25(1):1\u201323","journal-title":"Funct Integ Genom"},{"issue":"2","key":"2757_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jss.2003.09.010","volume":"117","author":"MS Duxbury","year":"2004","unstructured":"Duxbury MS, Whang EE (2004) RNA interference: a practical approach. J Surg Res 117(2):339\u2013344","journal-title":"J Surg Res"},{"issue":"6","key":"2757_CR41","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli M, Manoharan M (2023) Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res 51(6):2529\u20132573","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2757_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/156652308784746440","volume":"8","author":"A Ehrhardt","year":"2008","unstructured":"Ehrhardt A et al (2008) Episomal vectors for gene therapy. Curr Gene Ther 8(3):147\u2013161","journal-title":"Curr Gene Ther"},{"issue":"11","key":"2757_CR43","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1042\/BCJ20170793","volume":"475","author":"A Eid","year":"2018","unstructured":"Eid A, Alshareef S, Mahfouz MM (2018) CRISPR base editors: genome editing without double-stranded breaks. Biochem J 475(11):1955\u20131964","journal-title":"Biochem J"},{"issue":"3","key":"2757_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.sbi.2005.05.006","volume":"15","author":"W Filipowicz","year":"2005","unstructured":"Filipowicz W et al (2005) Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 15(3):331\u2013341","journal-title":"Curr Opin Struct Biol"},{"issue":"4910","key":"2757_CR45","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1126\/science.2660259","volume":"244","author":"T Friedmann","year":"1989","unstructured":"Friedmann T (1989) Progress toward human gene therapy. Science 244(4910):1275\u20131281","journal-title":"Science"},{"key":"2757_CR46","doi-asserted-by":"publisher","first-page":"S4878","DOI":"10.4137\/OED.S4878","volume":"2","author":"AO Garba","year":"2010","unstructured":"Garba AO, Mousa SA (2010) Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis 2:S4878","journal-title":"Ophthalmol Eye Dis"},{"issue":"7","key":"2757_CR47","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","volume":"38","author":"NM Gaudelli","year":"2020","unstructured":"Gaudelli NM et al (2020) Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol 38(7):892\u2013900","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2757_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/crispr.2024.0036","volume":"7","author":"CA George","year":"2024","unstructured":"George CA et al (2024) Genome editing therapy for the blood: ex vivo success and in vivo prospects. Crispr j 7(5):231\u2013248","journal-title":"Crispr j"},{"issue":"1","key":"2757_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/sj.mn.7800121","volume":"9","author":"T Golden","year":"2002","unstructured":"Golden T, Dean NM, Honkanen RE (2002) Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue. Microcirculation 9(1):51\u201364","journal-title":"Microcirculation"},{"key":"2757_CR50","doi-asserted-by":"publisher","first-page":"1356578","DOI":"10.3389\/fmed.2024.1356578","volume":"11","author":"F Greco","year":"2024","unstructured":"Greco F, Cosentino M, Marino F (2024) The Italian breakthrough in CRISPR trials for rare diseases: a focus on beta-thalassemia and sickle cell disease treatment. Front Med 11:1356578","journal-title":"Front Med"},{"issue":"4","key":"2757_CR51","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/0092-8674(95)90082-9","volume":"81","author":"S Guo","year":"1995","unstructured":"Guo S, Kemphues KJ (1995) par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser\/Thr kinase that is asymmetrically distributed. Cell 81(4):611\u2013620","journal-title":"Cell"},{"issue":"12","key":"2757_CR52","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","volume":"30","author":"P Harmatz","year":"2022","unstructured":"Harmatz P et al (2022) First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B. Mol Ther 30(12):3587\u20133600","journal-title":"Mol Ther"},{"key":"2757_CR53","doi-asserted-by":"crossref","unstructured":"Hays P (2021) Translational personalized medicine: molecular profiling, druggable targets, and clinical genomic medicine. Adv Healthcare Person Med 609\u2013653","DOI":"10.1007\/978-3-030-80100-7_11"},{"key":"2757_CR54","unstructured":"Henderson N et al (2024) A spotlight on haemophilia therapies. Office of health economics"},{"issue":"1","key":"2757_CR55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.stem.2015.12.002","volume":"18","author":"WT Hendriks","year":"2016","unstructured":"Hendriks WT, Warren CR, Cowan CA (2016) Genome editing in human pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell 18(1):53\u201365","journal-title":"Cell Stem Cell"},{"issue":"3","key":"2757_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","volume":"65","author":"VE Hillary","year":"2023","unstructured":"Hillary VE, Ceasar SA (2023) A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering. Mol Biotechnol 65(3):311\u2013325","journal-title":"Mol Biotechnol"},{"issue":"1","key":"2757_CR57","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","volume":"19","author":"A Holm","year":"2022","unstructured":"Holm A et al (2022) Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. RNA Biol 19(1):594\u2013608","journal-title":"RNA Biol"},{"issue":"5962","key":"2757_CR58","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.1179555","volume":"327","author":"P Horvath","year":"2010","unstructured":"Horvath P, Barrangou R (2010) CRISPR\/Cas, the immune system of bacteria and archaea. Science 327(5962):167\u2013170","journal-title":"Science"},{"issue":"5","key":"2757_CR59","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1515\/mr-2022-0029","volume":"2","author":"C Huang","year":"2022","unstructured":"Huang C, Li Q, Li J (2022) Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives. Med Rev 2(5):471\u2013500","journal-title":"Med Rev"},{"key":"2757_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12964-025-02246-4","volume":"23","author":"K Hushmandi","year":"2025","unstructured":"Hushmandi K et al (2025) Gene therapy for age-related macular degeneration: a promising frontier in vision preservation. Cell Commun Signal 23:233","journal-title":"Cell Commun Signal"},{"key":"2757_CR61","doi-asserted-by":"crossref","unstructured":"Ibrahim N (2023) Navigating the complexity of rare diseases: challenges, innovations, and future directions. Glob J Med Therapeut 5(4)","DOI":"10.46982\/gjmt.2023.108"},{"issue":"35","key":"2757_CR62","doi-asserted-by":"publisher","first-page":"eabg2661","DOI":"10.1126\/sciadv.abg2661","volume":"7","author":"H-K Jang","year":"2021","unstructured":"Jang H-K et al (2021) High-purity production and precise editing of DNA base editing ribonucleoproteins. Sci Adv 7(35):eabg2661","journal-title":"Sci Adv"},{"issue":"6096","key":"2757_CR63","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M et al (2012) A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816\u2013821","journal-title":"Science"},{"issue":"17","key":"2757_CR64","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","volume":"21","author":"A Kantor","year":"2020","unstructured":"Kantor A, McClements ME, MacLaren RE (2020a) CRISPR-Cas9 DNA base-editing and prime-editing. Int J Mol Sci 21(17):6240","journal-title":"Int J Mol Sci"},{"issue":"17","key":"2757_CR65","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","volume":"21","author":"A Kantor","year":"2020","unstructured":"Kantor A, McClements ME, MacLaren RE (2020b) CRISPR-Cas9 DNA base-editing and prime-editing. Int J Mol Sci 21(17):6240","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2757_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1152\/physrev.00039.2017","volume":"99","author":"P Karagiannis","year":"2019","unstructured":"Karagiannis P et al (2019) Induced pluripotent stem cells and their use in human models of disease and development. Physiol Rev 99(1):79\u2013114","journal-title":"Physiol Rev"},{"issue":"8","key":"2757_CR67","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.3390\/cimb46080485","volume":"46","author":"E Kerwash","year":"2024","unstructured":"Kerwash E et al (2024) Regulatory assessment of Casgevy for the treatment of transfusion-dependent \u03b2-Thalassemia and Sickle Cell Disease with recurrent vaso-occlusive crises. Curr Issues Mol Biol 46(8):8209\u20138225","journal-title":"Curr Issues Mol Biol"},{"issue":"8","key":"2757_CR68","doi-asserted-by":"publisher","first-page":"533","DOI":"10.14348\/molcells.2017.0139","volume":"40","author":"MS Kim","year":"2017","unstructured":"Kim MS, Kini AG (2017) Engineering and application of zinc finger proteins and TALEs for biomedical research. Mol Cells 40(8):533\u2013541","journal-title":"Mol Cells"},{"key":"2757_CR69","doi-asserted-by":"publisher","first-page":"D481","DOI":"10.2741\/Klimatcheva","volume":"4","author":"E Klimatcheva","year":"1999","unstructured":"Klimatcheva E, Rosenblatt JD, Planelles V (1999) Lentiviral vectors and gene therapy. Front Biosci 4:D481\u2013D496","journal-title":"Front Biosci"},{"key":"2757_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-biochem-010909-095056","volume":"79","author":"A Klug","year":"2010","unstructured":"Klug A (2010) The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 79:213\u2013231","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"2757_CR71","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/imr.13293","volume":"322","author":"DB Kohn","year":"2024","unstructured":"Kohn DB (2024) Gene therapy for adenosine deaminase severe combined immune deficiency\u2014an unexpected journey of four decades. Immunol Rev 322(1):148\u2013156","journal-title":"Immunol Rev"},{"issue":"1","key":"2757_CR72","doi-asserted-by":"publisher","first-page":"160","DOI":"10.20538\/1682-0363-2020-1-160-171","volume":"19","author":"A Komina","year":"2020","unstructured":"Komina A, Lavrentiev S, Ruksha T (2020) MicroRNAs and small interfering RNAs as tools for the directed regulation of cellular processes for cancer therapy. Bull Siberian Med 19(1):160\u2013171","journal-title":"Bull Siberian Med"},{"issue":"4","key":"2757_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1640","volume":"12","author":"A Kotowska-Zimmer","year":"2021","unstructured":"Kotowska-Zimmer A, Pewinska M, Olejniczak M (2021) Artificial miRNAs as therapeutic tools: Challenges and opportunities. Wiley Interdisciplin Rev RNA 12(4):e1640","journal-title":"Wiley Interdisciplin Rev RNA"},{"key":"2757_CR74","unstructured":"Kymalainen H (2012) Development of viral & non-viral episomal vectors for gene therapy applications. University of London"},{"key":"2757_CR75","doi-asserted-by":"crossref","unstructured":"Lahoti S (2024) The revolution of clustered regularly interspaced short palindromic repeats-based therapies: From genetic diseases to cancer investigating how clustered regularly interspaced short palindromic repeats technology is being applied to treat genetic disorder. Innov Pharm Planet 64\u201368","DOI":"10.31690\/ipplanet.2024.v012i04.018"},{"issue":"3","key":"2757_CR76","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.tibtech.2009.11.007","volume":"28","author":"F Le Provost","year":"2010","unstructured":"Le Provost F et al (2010) Zinc finger nuclease technology heralds a new era in mammalian transgenesis. Trends Biotechnol 28(3):134\u2013141","journal-title":"Trends Biotechnol"},{"issue":"1","key":"2757_CR77","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/biomedicines10010158","volume":"10","author":"MJ Lee","year":"2022","unstructured":"Lee MJ, Lee I, Wang K (2022) Recent advances in RNA therapy and its carriers to treat the single-gene neurological disorders. Biomedicines 10(1):158","journal-title":"Biomedicines"},{"issue":"4","key":"2757_CR78","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ (2020) Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 21(4):255\u2013272","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2757_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H et al (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther 5(1):1","journal-title":"Signal Transduct Target Ther"},{"key":"2757_CR80","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug des Devel Ther 11:533\u2013545","journal-title":"Drug des Devel Ther"},{"issue":"6","key":"2757_CR81","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1021\/acsmaterialsau.3c00035","volume":"3","author":"J Lin","year":"2023","unstructured":"Lin J et al (2023) Combinational gene therapy toward cancer with nanoplatform: strategies and principles. ACS Mater Au 3(6):584\u2013599","journal-title":"ACS Mater Au"},{"issue":"11","key":"2757_CR82","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/sj.gt.3302048","volume":"10","author":"PR Lowenstein","year":"2003","unstructured":"Lowenstein PR, Castro MG (2003) Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther 10(11):946\u2013954","journal-title":"Gene Ther"},{"issue":"3","key":"2757_CR83","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molcel.2015.10.030","volume":"60","author":"E Ma","year":"2015","unstructured":"Ma E et al (2015) Single-stranded DNA cleavage by divergent CRISPR-Cas9 enzymes. Mol Cell 60(3):398\u2013407","journal-title":"Mol Cell"},{"issue":"7","key":"2757_CR84","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41434-023-00399-w","volume":"30","author":"E Melin","year":"2023","unstructured":"Melin E et al (2023) Combinatorial gene therapy for epilepsy: gene sequence positioning and AAV serotype influence expression and inhibitory effect on seizures. Gene Ther 30(7):649\u2013658","journal-title":"Gene Ther"},{"issue":"2","key":"2757_CR85","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR et al (2021) Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 29(2):464\u2013488","journal-title":"Mol Ther"},{"issue":"1","key":"2757_CR86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1134\/S0026893324010084","volume":"58","author":"EV Mikhaylova","year":"2024","unstructured":"Mikhaylova EV et al (2024) Prime-editing methods and pegRNA design programs. Mol Biol (Mosk) 58(1):22\u201339","journal-title":"Mol Biol (Mosk)"},{"issue":"12","key":"2757_CR87","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.3390\/ijms21124394","volume":"21","author":"P Morais","year":"2020","unstructured":"Morais P, Adachi H, Yu YT (2020) Suppression of nonsense mutations by new emerging technologies. Int J Mol Sci 21(12):4394","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2757_CR88","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/cells9071608","volume":"9","author":"M Naeem","year":"2020","unstructured":"Naeem M et al (2020) Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells 9(7):1608","journal-title":"Cells"},{"issue":"2","key":"2757_CR89","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/aihb.aihb_162_20","volume":"11","author":"Y Nalla","year":"2021","unstructured":"Nalla Y, Shah S (2021) A new era in molecular biology clustered regularly interspaced short palindromic repeats\/cas9 technology: a brief understanding. Adv Hum Biol 11(2):152\u2013156","journal-title":"Adv Hum Biol"},{"issue":"3","key":"2757_CR90","first-page":"194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK (2019) Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther 24(3):194\u2013203","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"2757_CR91","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","volume":"40","author":"JW Nelson","year":"2022","unstructured":"Nelson JW et al (2022) Engineered pegRNAs improve prime editing efficiency. Nat Biotechnol 40(3):402\u2013410","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2757_CR92","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12016-022-08950-0","volume":"65","author":"K Paris","year":"2023","unstructured":"Paris K, Wall LA (2023) The treatment of primary immune deficiencies: lessons learned and future opportunities. Clin Rev Allergy Immunol 65(1):19\u201330","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"2757_CR93","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1128\/mr.53.3.273-298.1989","volume":"53","author":"J Parker","year":"1989","unstructured":"Parker J (1989) Errors and alternatives in reading the universal genetic code. Microbiol Rev 53(3):273\u2013298","journal-title":"Microbiol Rev"},{"issue":"1\u20132","key":"2757_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hum.2023.29263.bfs","volume":"35","author":"A Philippidis","year":"2024","unstructured":"Philippidis A (2024) CASGEVY makes history as FDA approves first CRISPR\/Cas9 genome edited therapy. Hum Gene Ther 35(1\u20132):1\u20134","journal-title":"Hum Gene Ther"},{"issue":"12","key":"2757_CR95","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","volume":"19","author":"EM Porto","year":"2020","unstructured":"Porto EM et al (2020) Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov 19(12):839\u2013859","journal-title":"Nat Rev Drug Discov"},{"key":"2757_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.730873","volume":"12","author":"P Rattananon","year":"2021","unstructured":"Rattananon P et al (2021) The future of gene therapy for transfusion-dependent beta-thalassemia: the power of the lentiviral vector for genetically modified hematopoietic stem cells. Front Pharmacol 12:730873","journal-title":"Front Pharmacol"},{"issue":"20","key":"2757_CR97","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1001\/jama.2024.5613","volume":"331","author":"DM Rind","year":"2024","unstructured":"Rind DM (2024) The FDA and gene therapy for Duchenne muscular dystrophy. JAMA 331(20):1705\u20131706","journal-title":"JAMA"},{"issue":"11","key":"2757_CR98","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts TC, Wood MJ, Davies KE (2023) Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discovery 22(11):917\u2013934","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"2757_CR99","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41576-022-00556-8","volume":"24","author":"ME Rogalska","year":"2023","unstructured":"Rogalska ME, Vivori C, Valc\u00e1rcel J (2023) Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects. Nat Rev Genet 24(4):251\u2013269","journal-title":"Nat Rev Genet"},{"issue":"2","key":"2757_CR100","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0169-409X(95)00020-8","volume":"18","author":"Y Rojanasakul","year":"1996","unstructured":"Rojanasakul Y (1996) Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv Drug Deliv Rev 18(2):115\u2013131","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2757_CR101","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2017.12.008","volume":"26","author":"G Ronzitti","year":"2018","unstructured":"Ronzitti G, Mingozzi F (2018) Combination therapy is the new gene therapy? Mol Ther 26(1):12\u201314","journal-title":"Mol Ther"},{"key":"2757_CR102","unstructured":"Royal S et al (2020) The National Academies Collection: Reports funded by National Institutes of Health, in Heritable Human Genome Editing. 2020, National Academies Press (US) Copyright 2020 by the National Academy of Sciences. All rights reserved: Washington (DC)"},{"issue":"3","key":"2757_CR103","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0098-2997(01)00004-8","volume":"22","author":"GM Rubanyi","year":"2001","unstructured":"Rubanyi GM (2001) The future of human gene therapy. Mol Aspects Med 22(3):113\u2013142","journal-title":"Mol Aspects Med"},{"issue":"36","key":"2757_CR104","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1200\/EDBK_155975","volume":"35","author":"P Ruff","year":"2016","unstructured":"Ruff P et al (2016) Access to cancer therapeutics in low-and middle-income countries. Am Soc Clin Oncol Educ Book 35(36):58\u201365","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7\u20138","key":"2757_CR105","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41434-021-00263-9","volume":"28","author":"J Scholefield","year":"2021","unstructured":"Scholefield J, Harrison PT (2021) Prime editing\u2013an update on the field. Gene Ther 28(7\u20138):396\u2013401","journal-title":"Gene Ther"},{"issue":"7","key":"2757_CR106","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1517\/14712598.2013.779249","volume":"13","author":"MM Segura","year":"2013","unstructured":"Segura MM et al (2013) New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 13(7):987\u20131011","journal-title":"Expert Opin Biol Ther"},{"key":"2757_CR107","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-0716-2301-5_2","volume":"2495","author":"Y Shamshirgaran","year":"2022","unstructured":"Shamshirgaran Y et al (2022) Tools for efficient genome editing; ZFN, TALEN, and CRISPR. Methods Mol Biol 2495:29\u201346","journal-title":"Methods Mol Biol"},{"issue":"15","key":"2757_CR108","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","volume":"126","author":"R Sharma","year":"2015","unstructured":"Sharma R et al (2015) In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126(15):1777\u20131784","journal-title":"Blood"},{"issue":"2","key":"2757_CR109","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13543784.2021.1868434","volume":"30","author":"O Sheikh","year":"2021","unstructured":"Sheikh O, Yokota T (2021) Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. Expert Opin Investig Drugs 30(2):167\u2013176","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2757_CR110","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41467-021-21921-x","volume":"12","author":"Y Shiromoto","year":"2021","unstructured":"Shiromoto Y et al (2021) ADAR1 RNA editing enzyme regulates R-loop formation and genome stability at telomeres in cancer cells. Nat Commun 12(1):1654","journal-title":"Nat Commun"},{"key":"2757_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2024.116599","volume":"343","author":"M Siermann","year":"2024","unstructured":"Siermann M et al (2024) \u201cAre we not going too far?\u201d: Socio-ethical considerations of preimplantation genetic testing using polygenic risk scores according to healthcare professionals. Soc Sci Med 343:116599","journal-title":"Soc Sci Med"},{"key":"2757_CR112","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s00018-005-5391-x","volume":"63","author":"M Soller","year":"2006","unstructured":"Soller M (2006) Pre-messenger RNA processing and its regulation: a genomic perspective. Cell Mol Life Sci CMLS 63:796\u2013819","journal-title":"Cell Mol Life Sci CMLS"},{"key":"2757_CR113","doi-asserted-by":"crossref","unstructured":"Steinbrook R (2008) The Gelsinger Case. The Oxford textbook of clinical research ethics, 110\u2013120","DOI":"10.1093\/oso\/9780195168655.003.0011"},{"issue":"22","key":"2757_CR114","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.3390\/ijms252212284","volume":"25","author":"H Tani","year":"2024","unstructured":"Tani H (2024) Recent advances and prospects in RNA drug development. Int J Mol Sci 25(22):12284","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2757_CR115","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1097\/MS9.0000000000002478","volume":"86","author":"H Tariq","year":"2024","unstructured":"Tariq H et al (2024) CRISPR\/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review. Ann Med Surg (Lond) 86(10):5938\u20135946","journal-title":"Ann Med Surg (Lond)"},{"key":"2757_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144486","author":"P Tebas","year":"2021","unstructured":"Tebas P et al (2021) CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI144486","journal-title":"J Clin Invest"},{"issue":"5","key":"2757_CR117","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/hcs2.115","volume":"3","author":"A Thacharodi","year":"2024","unstructured":"Thacharodi A et al (2024) Revolutionizing healthcare and medicine: the impact of modern technologies for a healthier future\u2014a comprehensive review. Health Care Sci 3(5):329\u2013349","journal-title":"Health Care Sci"},{"issue":"5","key":"2757_CR118","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1089\/crispr.2024.0082","volume":"7","author":"FD Urnov","year":"2024","unstructured":"Urnov FD (2024) Give Cas a chance: an actionable path to a platform for CRISPR cures. Crispr j 7(5):212\u2013219","journal-title":"Crispr j"},{"issue":"4","key":"2757_CR119","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/humupd\/dmw005","volume":"22","author":"R Vassena","year":"2016","unstructured":"Vassena R et al (2016) Genome engineering through CRISPR\/Cas9 technology in the human germline and pluripotent stem cells. Hum Reprod Update 22(4):411\u2013419","journal-title":"Hum Reprod Update"},{"key":"2757_CR120","doi-asserted-by":"crossref","unstructured":"Wachapatthana U, Thanupran T (2021) Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR): a novel genomic modifying","DOI":"10.52403\/ijshr.20210744"},{"issue":"12","key":"2757_CR121","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.3390\/molecules25122866","volume":"25","author":"A Wahane","year":"2020","unstructured":"Wahane A et al (2020) Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy. Molecules 25(12):2866","journal-title":"Molecules"},{"issue":"6","key":"2757_CR122","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/crispr.2022.0084","volume":"5","author":"D Wang","year":"2022","unstructured":"Wang D et al (2022) Prime editing in mammals: the next generation of precision genome editing. Crispr j 5(6):746\u2013768","journal-title":"Crispr j"},{"key":"2757_CR123","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-7774-1_2","volume":"1767","author":"CB Waryah","year":"2018","unstructured":"Waryah CB et al (2018) Zinc fingers, TALEs, and CRISPR systems: a comparison of tools for epigenome editing. Methods Mol Biol 1767:19\u201363","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2757_CR124","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BJ20140295","volume":"462","author":"DA Wright","year":"2014","unstructured":"Wright DA et al (2014) TALEN-mediated genome editing: prospects and perspectives. Biochem J 462(1):15\u201324","journal-title":"Biochem J"},{"key":"2757_CR125","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1016\/j.csbj.2022.06.015","volume":"20","author":"X Wu","year":"2022","unstructured":"Wu X et al (2022) Development and clinical translation of ex vivo gene therapy. Comput Struct Biotechnol J 20:2986\u20133003","journal-title":"Comput Struct Biotechnol J"},{"issue":"7","key":"2757_CR126","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue C, Greene EC (2021) DNA repair pathway choices in CRISPR-Cas9-mediated genome editing. Trends Genet 37(7):639\u2013656","journal-title":"Trends Genet"},{"key":"2757_CR127","doi-asserted-by":"publisher","DOI":"10.1017\/S0033583519000052","volume":"52","author":"F Zhang","year":"2019","unstructured":"Zhang F (2019) Development of CRISPR-Cas systems for genome editing and beyond. Q Rev Biophys 52:e6","journal-title":"Q Rev Biophys"},{"issue":"8","key":"2757_CR128","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.tibtech.2023.03.004","volume":"41","author":"Z Zhao","year":"2023","unstructured":"Zhao Z et al (2023) Prime editing: advances and therapeutic applications. Trends Biotechnol 41(8):1000\u20131012","journal-title":"Trends Biotechnol"},{"issue":"3","key":"2757_CR129","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<964::AID-IMMU964>3.0.CO;2-P","volume":"29","author":"L Zhong","year":"1999","unstructured":"Zhong L et al (1999) Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29(3):964\u2013972","journal-title":"Eur J Immunol"},{"issue":"12","key":"2757_CR130","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"R Zufferey","year":"1998","unstructured":"Zufferey R et al (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72(12):9873\u20139880","journal-title":"J Virol"}],"container-title":["Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00439-025-02757-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:04:30Z","timestamp":1751447070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00439-025-02757-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":129,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2757"],"URL":"https:\/\/doi.org\/10.1007\/s00439-025-02757-7","relation":{},"ISSN":["0340-6717","1432-1203"],"issn-type":[{"type":"print","value":"0340-6717"},{"type":"electronic","value":"1432-1203"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No human or animal experiments were performed by the authors for this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"All the authors who are part of this manuscript have given their approval to the final version of this manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}